Vol. 6 No. 11 (2026): November
Reimbursement Reviews

Mepolizumab (Nucala)

decorative image of the issue cover

Published November 3, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses mepolizumab (Nucala), 100 mg/mL solution for subcutaneous injection. Prefilled autoinjector or safety syringe.
  • Indication:
    • Proposed indication at the time of review: mepolizumab is indicated as add-on maintenance treatment for adult patients with COPD with an eosinophilic phenotype.
    • Approved indication: as add-on maintenance treatment in adult patients with COPD characterized by raised blood eosinophils inadequately controlled by the combination of an ICS, a LABA, and a LAMA.